http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Novocure to Present at Cowen and Company 36th Annual Health Care Conference
-
Novocure (NVCR) Announces Positive Coverage Decision for Optune by Anthem (ANTM)
-
Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma
-
Novocure's (NVCR) Results from TTFields + Ttemozolomide Phase 3 in Newly Diagnosed GBM Will be Publish in ASCO Report
-
Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report
-
Novocure to Report Fourth Quarter, Year-End Financial Results
-
Novocure (NVCR) Plans Presentation of Positive Phase 2 PANOVA Data at ASCO GI
-
Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancre
-
Novocure Announces Preliminary 2015 Operating Statistics
-
Novocure (NVCR) Announces Submission of PMA to Japanese PMDA for Optune
-
Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients
-
Novocure (NVCR) Announces Filing of PMA Supplement with FDA for Optune System
-
Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System
-
Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference
-
Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data
-
Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma
-
New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports
-
Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts
-
Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer
-
New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence
-
Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015
-
Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
-
Novocure Reports Third Quarter 2015 Operating and Financial Results
-
NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option
-
Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015
-
Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26
-
NovoCure Limited Announces Closing of Initial Public Offering
-
FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
-
ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
-
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
-
NovoCure Limited (Nasdaq: NVCR) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
-
NovoCure Limited (Nasdaq: NVCR) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
-
NovoCure Limited Announces Launch of Initial Public Offering

